RXRX (Recursion Pharmaceuticals) FFO


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.51
GF Value $4.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.51 is trading 15.4% below its estimated GF Value™ of $4.15. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

  • FFO:
  • GF Value™: $4.15 vs. price of $3.51 (15.4% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.51
Price
$4.15
GF Value